Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.

Name: Kaimen Rigor review — Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
Item: Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
Rating: 96
Author: Alpha1

Cao B, Wang Y, Lu H, Huang C, Yang Y, Shang L, Chen Z, Jiang R, Liu Y, Lin L, Peng P, Wang F, Gong F, Hu H, Cheng C, Yao X, Ye X, Zhou H, Shen Y, Liu C, Wang C, Yi Z, Hu B, Xu J, Gu X, Shen J, Xu Y, Zhang L, Fan J, Tang R, Wang C

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 4.25★ (Strong), 0 critical, 2 high issues for “Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.

Read full text (PMC)

DOI

10.1056/NEJMoa2301425

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/4e89a70c-9ece-43f0-ac90-37dc0269acbb" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/4e89a70c-9ece-43f0-ac90-37dc0269acbb/badge" alt="Kaimen Rigor review — 4.25★ (Strong), 0 critical, 2 high issues for “Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

29cf25638c7cc47e6adcabcb4e2e557e5cc65dcf2579079d48a53ac448d683c5

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.

Paper source

Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

4.25 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 3 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Findings by category

101ArithmeticNumerical inconsistencies 02OverreachNone found 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit4 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported phase 2-3 randomized controlled trial with rigorous design, clear ethical approvals, and appropriate statistical methods. The main weakness is the vague data sharing statement, which lacks concrete access details. Minor copyedit issues (e.g., subject-verb agreement) do not affect scientific integrity.

Both reviewers independently scored all eight dimensions and agreed on every status. The study type is interventional (randomized controlled trial). Non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification recomputed only 1 test; other statistics were not machine-verified but no errors were flagged.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

Overstated conclusions

None found

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Checked — nothing surfaced.

5 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior research on other 3CLpro inhibitors (nirmatrelvir, ensitrelvir) and simnotrelvir's in vitro activity and phase 1B results, establishing the rationale for the trial. The premise is logically connected to the study objective of evaluating simnotrelvir's efficacy and safety. Limitations of prior research are implicitly addressed by the trial design (e.g., randomized, placebo-controlled), though not explicitly discussed in the introduction.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior work on SARS-CoV-2 antivirals and simnotrelvir's in vitro and phase 1B data, and logically links this to the trial's objectives.

Evidence

“Several small-molecule drugs (e.g., nirmatrelvir and ensitrelvir ) targeting the SARS-CoV-2 3-chymotrypsin–like cysteine protease enzyme (3CLpro, also known as main protease [Mpro]) are available.”

Introduction ¶1Find in source

“In vitro simnotrelvir showed antiviral activity with a half maximal effective concentration of 43 nmol per liter against the SARS-CoV-2 omicron variant B.1.1.529.1”

Introduction ¶2Find in source

absence[Introduction]

Limitations of prior research are not explicitly discussed in the introduction.

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior work on SARS-CoV-2 antivirals and simnotrelvir's preclinical and early clinical data, and provides a logical rationale for the trial.

Evidence

“Simnotrelvir (SIM0417) is an oral small-molecule antiviral agent that also targets the SARS-CoV-2 3CLpro.”

Introduction ¶2Find in source

“We conducted a phase 2–3, double-blind, randomized, placebo-controlled trial to investigate the efficacy and safety of simnotrelvir plus ritonavir in the treatment of adult patients with mild-to-moderate Covid-19.”

IntroductionFind in source

absence[Introduction]

Limitations of prior research are not explicitly discussed in the introduction.

Randomization was performed via a centralized interactive-response technology system with 1:1 allocation, stratified by region, age, and vaccination status. Blinding of patients and investigators is described, and the placebo was visually identical. A power analysis was conducted, and inclusion/exclusion criteria were prespecified. The modified intention-to-treat-1 population was defined as the main analysis population. Outlier handling is addressed through the definition of analysis populations and missing data handling (referenced to protocol). Controls are inherent in the placebo arm. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, double-blind, placebo-controlled, with a centralized randomization system, stratification, and a prespecified primary analysis population.

Evidence

“Eligible patients were randomly assigned, in a 1:1 ratio through a centralized, interactive-response technology system”

MethodsFind in source

“Patients and investigators were unaware of the randomization assignments.”

MethodsFind in source

“we calculated that a sample of 960 patients, with 949 of these patients having sustained resolution of symptoms, would provide at least 90% power to detect a 24-hour difference in the median time to sustained resolution of symptoms”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous: randomized, double-blind, placebo-controlled, with a centralized randomization system, stratification, and a prespecified primary analysis population.

Evidence

“Eligible patients were randomly assigned, in a 1:1 ratio through a centralized, interactive-response technology system, to receive either 750 mg of simnotrelvir (two tablets, 375 mg per tablet) plus 100 mg of ritonavir or matching placebo twice daily for 5 days.”

MethodsFind in source

“Patients and investigators were unaware of the randomization assignments.”

MethodsFind in source

“Assuming that only 80% of 1200 patients enrolled in the trial would be included in the primary analysis, we calculated that a sample of 960 patients, with 949 of these patients having sustained resolution of symptoms, would provide at least 90% power to detect a 24-hour difference in the median time to sustained resolution of symptoms between the simnotrelvir group and the placebo group at a two-sided significance level of 0.05.”

Statistical analysisFind in source

Sex is reported for the full analysis population (58.1% male in simnotrelvir group, 60.1% in placebo). Age is reported as median (IQR) of 35 years. Health status is captured through risk factors and disease severity. Demographics are adequately reported for a clinical trial. Species/strain and housing conditions are not applicable.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, and risk factors, though age is reported as median with IQR rather than full age distribution.

Evidence

“Male sex — no. (%) | 333 (58.1) | 340 (60.1) | 673 (59.1)”

Table 1Find in source

“Median age (IQR) — yr | 35 (28–47) | 35 (28–47) | 35 (28–47)”

Table 1Find in source

“At least one risk factor | 302 (52.7) | 307 (54.2) | 609 (53.5)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, and risk factors. Since both sexes are enrolled, sex justification is not applicable.

Evidence

“Male sex — no. (%) | 333 (58.1) | 340 (60.1) | 673 (59.1)”

Table 1Find in source

“Median age (IQR) — yr | 35 (28–47) | 35 (28–47) | 35 (28–47)”

Table 1Find in source

“Overall, the trial recruited a fully vaccinated and relatively young population, with approximately half the patients (609 [53.5%]) having at least one risk factor for severe Covid-19 (Table S6).”

Results ¶2Find in source

The trial was approved by the ethics committee at each site, and written informed consent was obtained from all patients. The trial was conducted in accordance with the Declaration of Helsinki and ICH-GCP guidelines. This satisfies all applicable criteria for a human interventional trial.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval and informed consent are clearly documented, with compliance to Declaration of Helsinki and ICH-GCP.

Evidence

“The trial was approved by the ethics committee at each site.”

MethodsFind in source

“Written informed consent was obtained from all patients.”

MethodsFind in source

“The trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approval and informed consent are clearly documented, with a named ethics committee approval and written informed consent from all patients.

Evidence

“The trial was approved by the ethics committee at each site.”

MethodsFind in source

“Written informed consent was obtained from all patients.”

MethodsFind in source

“The trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines.”

MethodsFind in source

The investigational product is clearly identified: simnotrelvir 750 mg plus ritonavir 100 mg, with formulation details (two tablets, 375 mg per tablet). The placebo is described as visually identical. Statistical software (SAS 9.4) is identified. No antibodies, cell lines, or other bench reagents are used, so those criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (simnotrelvir and ritonavir) is identified with dose and regimen, and statistical software is identified.

Evidence

“to receive either 750 mg of simnotrelvir (two tablets, 375 mg per tablet) plus 100 mg of ritonavir or matching placebo twice daily for 5 days.”

MethodsFind in source

“All P values are two-sided and were calculated with SAS software, version 9.4 (SAS Institute).”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (simnotrelvir plus ritonavir) is identified with dose and regimen, and the statistical software is identified. Bench resources are not applicable.

Evidence

MethodsFind in source

“All P values are two-sided and were calculated with SAS software, version 9.4 (SAS Institute).”

Statistical analysisFind in source

The primary analysis used a Peto-Prentice test with stratification, and p-values are reported exactly (P=0.006). Effect sizes are reported with 95% CIs. Statistical software is identified. Data presentation includes Kaplan-Meier curves and per-group n. Assumptions are handled by design (stratified test, mixed models for viral load). Mathematical plausibility checks were not performed due to lack of recomputable statistics.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals for the primary endpoint, and software identified.

Evidence

“P=0.006 by Peto–Prentice test”

AbstractFind in source

“median difference, −35.8 hours [95% CI, −60.1 to −12.4]”

AbstractFind in source

“All P values are two-sided and were calculated with SAS software, version 9.4 (SAS Institute).”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals for the primary endpoint. The analysis is consistent with clinical trial reporting standards.

Evidence

“P=0.006 by Peto–Prentice test”

AbstractFind in source

“median difference, −35.8 hours [95% CI, −60.1 to −12.4]”

AbstractFind in source

“All P values are two-sided and were calculated with SAS software, version 9.4 (SAS Institute).”

Statistical analysisFind in source

The paper mentions a 'Data Sharing Statement' but the actual content is not provided in the text. No repository deposit or accession numbers are mentioned. Code sharing is not applicable as no custom code is described. The data availability statement is vague, lacking a concrete access route.

Sub-criteria

code sharingN/A

accession numbersNOT REPORTED

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data sharing statement is mentioned but not detailed in the provided text; no repository or accession numbers are given.

Evidence

“Data Sharing Statement A provided by the authors is available with the full text of this article at NEJM.org.”

End of paperFind in source

absence[Entire paper]

No repository deposit is mentioned.

absence[Entire paper]

No accession numbers are mentioned.

WARNReviewer 2· 80% conf

A data sharing statement is mentioned but not detailed in the main text; no repository or accession numbers are provided. Code sharing is not applicable.

Evidence

“Data Sharing Statement A provided by the authors is available with the full text of this article at NEJM.org.”

End of articleFind in source

absence[Data Sharing Statement]

No repository deposit is mentioned.

Trial registration number is provided (NCT05506176). Methods are comprehensive. Limitations are explicitly discussed (e.g., young population, potential unblinding due to ritonavir taste). Conclusions are appropriately cautious. Funding and COI are stated. Reporting guideline adherence is implied by NEJM standards but not explicitly mentioned.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional to the evidence.

Evidence

“ClinicalTrials.gov number, NCT05506176”

ConclusionFind in source

“the placebo contained only excipients; therefore, unblinding may have occurred in some patients, given the unique taste of ritonavir.”

Discussion ¶5Find in source

“Supported by Jiangsu Simcere Pharmaceutical.”

FootnotesFind in source

PASSReviewer 2· 95% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional. Funding and COI are disclosed.

Evidence

“ClinicalTrials.gov number, NCT05506176”

ConclusionFind in source

“Third, the recruited population was relatively young. The efficacy and safety among older patients still warrants investigations in future research.”

Discussion ¶5Find in source

“Supported by Jiangsu Simcere Pharmaceutical.”

FootnotesFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 19 references by DOI: 3 verified — 16 no DOI (shown, not verified).

1 data/code link checked; 1 live.

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly typo, consistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and trustworthy, with no major rigor gaps. An informed reader should weigh the vague data sharing statement and the lack of explicit CONSORT adherence as minor transparency limitations, but these do not undermine the validity of the findings. No erratum or re-analysis is warranted based on the evidence reviewed.

1.
HIGHdata code
Expand the Data Sharing Statement in the main text to specify the mechanism for accessing de-identified patient data (e.g., via a data access committee or a repository like Vivli) and the conditions for access.
The current statement is vague and does not provide a concrete access route, which is a transparency gap for a data-driven clinical trial.
2.
HIGHreporting
Explicitly state adherence to CONSORT reporting guidelines in the Methods or a separate section, and consider submitting the CONSORT checklist as supplementary material.
Explicit guideline adherence enhances transparency and is expected for randomized trials.
3.
MEDIUMreporting
Clarify the handling of missing data in the statistical analysis section, as it is only referenced to the protocol.
Readers need to know how missing data were handled to assess the robustness of the primary analysis.
4.
MEDIUMreporting
Provide a CONSORT flow diagram in the main text to enhance transparency of patient disposition.
A flow diagram clarifies the number of patients excluded at each stage and supports the reported analysis populations.
5.
MEDIUMreporting
Include a statement on the availability of the full trial protocol and statistical analysis plan.
Providing access to the protocol and SAP supports reproducibility and transparency.
6.
MEDIUMreporting
Provide more detail on the randomization implementation (e.g., block sizes, allocation concealment) in the main text.
Additional detail on randomization strengthens the description of the trial design.
7.
LOWcopyedit
Fix the subject-verb agreement error in the Abstract and Methods: change 'Two efficacy interim analysis were planned' to 'Two efficacy interim analyses were planned'.
Correct grammar improves professionalism and readability.
8.
LOWcopyedit
Ensure consistent use of 'analysis' vs 'analyses' throughout the manuscript.
Consistency in terminology avoids confusion.
9.
LOWdata code
Consider depositing de-identified aggregate data or statistical analysis code in a public repository to enhance transparency.
Public data/code deposit increases reproducibility and reader trust.

Full text (37,449 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.

Read full text (PMC)

DOI

10.1056/NEJMoa2301425

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/4e89a70c-9ece-43f0-ac90-37dc0269acbb" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/4e89a70c-9ece-43f0-ac90-37dc0269acbb/badge" alt="Kaimen Rigor review — 4.25★ (Strong), 0 critical, 2 high issues for “Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

29cf25638c7cc47e6adcabcb4e2e557e5cc65dcf2579079d48a53ac448d683c5

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

4.25 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 3 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Findings by category

101ArithmeticNumerical inconsistencies 02OverreachNone found 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit4 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

Overstated conclusions

None found

Checked — nothing surfaced.

5 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior work on SARS-CoV-2 antivirals and simnotrelvir's in vitro and phase 1B data, and logically links this to the trial's objectives.

Evidence

Introduction ¶1Find in source

“In vitro simnotrelvir showed antiviral activity with a half maximal effective concentration of 43 nmol per liter against the SARS-CoV-2 omicron variant B.1.1.529.1”

Introduction ¶2Find in source

absence[Introduction]

Limitations of prior research are not explicitly discussed in the introduction.

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior work on SARS-CoV-2 antivirals and simnotrelvir's preclinical and early clinical data, and provides a logical rationale for the trial.

Evidence

“Simnotrelvir (SIM0417) is an oral small-molecule antiviral agent that also targets the SARS-CoV-2 3CLpro.”

Introduction ¶2Find in source

IntroductionFind in source

absence[Introduction]

Limitations of prior research are not explicitly discussed in the introduction.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, double-blind, placebo-controlled, with a centralized randomization system, stratification, and a prespecified primary analysis population.

Evidence

“Eligible patients were randomly assigned, in a 1:1 ratio through a centralized, interactive-response technology system”

MethodsFind in source

“Patients and investigators were unaware of the randomization assignments.”

MethodsFind in source

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous: randomized, double-blind, placebo-controlled, with a centralized randomization system, stratification, and a prespecified primary analysis population.

Evidence

MethodsFind in source

“Patients and investigators were unaware of the randomization assignments.”

MethodsFind in source

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, and risk factors, though age is reported as median with IQR rather than full age distribution.

Evidence

“Male sex — no. (%) | 333 (58.1) | 340 (60.1) | 673 (59.1)”

Table 1Find in source

“Median age (IQR) — yr | 35 (28–47) | 35 (28–47) | 35 (28–47)”

Table 1Find in source

“At least one risk factor | 302 (52.7) | 307 (54.2) | 609 (53.5)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, and risk factors. Since both sexes are enrolled, sex justification is not applicable.

Evidence

“Male sex — no. (%) | 333 (58.1) | 340 (60.1) | 673 (59.1)”

Table 1Find in source

“Median age (IQR) — yr | 35 (28–47) | 35 (28–47) | 35 (28–47)”

Table 1Find in source

Results ¶2Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval and informed consent are clearly documented, with compliance to Declaration of Helsinki and ICH-GCP.

Evidence

“The trial was approved by the ethics committee at each site.”

MethodsFind in source

“Written informed consent was obtained from all patients.”

MethodsFind in source

“The trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approval and informed consent are clearly documented, with a named ethics committee approval and written informed consent from all patients.

Evidence

“The trial was approved by the ethics committee at each site.”

MethodsFind in source

“Written informed consent was obtained from all patients.”

MethodsFind in source

“The trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (simnotrelvir and ritonavir) is identified with dose and regimen, and statistical software is identified.

Evidence

“to receive either 750 mg of simnotrelvir (two tablets, 375 mg per tablet) plus 100 mg of ritonavir or matching placebo twice daily for 5 days.”

MethodsFind in source

“All P values are two-sided and were calculated with SAS software, version 9.4 (SAS Institute).”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (simnotrelvir plus ritonavir) is identified with dose and regimen, and the statistical software is identified. Bench resources are not applicable.

Evidence

MethodsFind in source

“All P values are two-sided and were calculated with SAS software, version 9.4 (SAS Institute).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals for the primary endpoint, and software identified.

Evidence

“P=0.006 by Peto–Prentice test”

AbstractFind in source

“median difference, −35.8 hours [95% CI, −60.1 to −12.4]”

AbstractFind in source

“All P values are two-sided and were calculated with SAS software, version 9.4 (SAS Institute).”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals for the primary endpoint. The analysis is consistent with clinical trial reporting standards.

Evidence

“P=0.006 by Peto–Prentice test”

AbstractFind in source

“median difference, −35.8 hours [95% CI, −60.1 to −12.4]”

AbstractFind in source

“All P values are two-sided and were calculated with SAS software, version 9.4 (SAS Institute).”

Statistical analysisFind in source

Sub-criteria

code sharingN/A

accession numbersNOT REPORTED

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data sharing statement is mentioned but not detailed in the provided text; no repository or accession numbers are given.

Evidence

“Data Sharing Statement A provided by the authors is available with the full text of this article at NEJM.org.”

End of paperFind in source

absence[Entire paper]

No repository deposit is mentioned.

absence[Entire paper]

No accession numbers are mentioned.

WARNReviewer 2· 80% conf

A data sharing statement is mentioned but not detailed in the main text; no repository or accession numbers are provided. Code sharing is not applicable.

Evidence

“Data Sharing Statement A provided by the authors is available with the full text of this article at NEJM.org.”

End of articleFind in source

absence[Data Sharing Statement]

No repository deposit is mentioned.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional to the evidence.

Evidence

“ClinicalTrials.gov number, NCT05506176”

ConclusionFind in source

“the placebo contained only excipients; therefore, unblinding may have occurred in some patients, given the unique taste of ritonavir.”

Discussion ¶5Find in source

“Supported by Jiangsu Simcere Pharmaceutical.”

FootnotesFind in source

PASSReviewer 2· 95% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional. Funding and COI are disclosed.

Evidence

“ClinicalTrials.gov number, NCT05506176”

ConclusionFind in source

“Third, the recruited population was relatively young. The efficacy and safety among older patients still warrants investigations in future research.”

Discussion ¶5Find in source

“Supported by Jiangsu Simcere Pharmaceutical.”

FootnotesFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 19 references by DOI: 3 verified — 16 no DOI (shown, not verified).

1 data/code link checked; 1 live.

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly typo, consistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHdata code
Expand the Data Sharing Statement in the main text to specify the mechanism for accessing de-identified patient data (e.g., via a data access committee or a repository like Vivli) and the conditions for access.
The current statement is vague and does not provide a concrete access route, which is a transparency gap for a data-driven clinical trial.
2.
HIGHreporting
Explicitly state adherence to CONSORT reporting guidelines in the Methods or a separate section, and consider submitting the CONSORT checklist as supplementary material.
Explicit guideline adherence enhances transparency and is expected for randomized trials.
3.
MEDIUMreporting
Clarify the handling of missing data in the statistical analysis section, as it is only referenced to the protocol.
Readers need to know how missing data were handled to assess the robustness of the primary analysis.
4.
MEDIUMreporting
Provide a CONSORT flow diagram in the main text to enhance transparency of patient disposition.
A flow diagram clarifies the number of patients excluded at each stage and supports the reported analysis populations.
5.
MEDIUMreporting
Include a statement on the availability of the full trial protocol and statistical analysis plan.
Providing access to the protocol and SAP supports reproducibility and transparency.
6.
MEDIUMreporting
Provide more detail on the randomization implementation (e.g., block sizes, allocation concealment) in the main text.
Additional detail on randomization strengthens the description of the trial design.
7.
LOWcopyedit
Fix the subject-verb agreement error in the Abstract and Methods: change 'Two efficacy interim analysis were planned' to 'Two efficacy interim analyses were planned'.
Correct grammar improves professionalism and readability.
8.
LOWcopyedit
Ensure consistent use of 'analysis' vs 'analyses' throughout the manuscript.
Consistency in terminology avoids confusion.
9.
LOWdata code
Consider depositing de-identified aggregate data or statistical analysis code in a public repository to enhance transparency.
Public data/code deposit increases reproducibility and reader trust.

Full text (37,449 chars)Analyzed: Aug 16, 2026